title: Long-term course of interferon-treated chronic hepatitis C.
abstract: OBJECTIVE
  To evaluate whether sustained response to a-interferon improves clinical outcome in patients with chronic hepatitis C.
  
  
  METHODS
  A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with a-interferon in two trials (mean follow-up 62.1 months, range 7-109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of a-2b or a-nl interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon.
  
  
  RESULTS
  Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. At the end of follow-up, 56 out of 62 sustained responders (90.3%) were serum HCV RNA negative. No biochemical relapse after 12 months was seen in sustained responders, regardless of initial histology, HCV genotype or persistence of HCV RNA. Although three died of non-hepatic causes, no liver-related events were observed among sustained responders. Complications of liver disease occurred in 34 relapsers/non-responders: nine hepatocellular carcinomas, 21 ascites and four portal hypertensive bleedings. Eleven relapsers/nonresponders died: eight of hepatic and three of non-hepatic causes. Event-free survival was significantly longer in sustained responders than in all the remaining patients. In a regression analysis, sustained response to interferon, low age and absence of cirrhosis were independent predictors of event-free survival.
  
  
  CONCLUSIONS
  Hepatitis C virus is probably eradicated and progression of liver disease is prevented in most patients who remain HCV RNA negative with normal transaminases for more than 1 year after stopping treatment.
authors.affiliation: Istituto Metodologie Diagnostiche Avanzate, Consiglio Nazionale delle Ricerche, Palermo, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Cammà
authors.forename: V
authors.initials: V
authors.lastname: Di Marco
authors.forename: O
authors.initials: O
authors.lastname: Lo Iacono
authors.forename: P
authors.initials: P
authors.lastname: Almasio
authors.forename: M
authors.initials: M
authors.lastname: Giunta
authors.forename: P
authors.initials: P
authors.lastname: Fuschi
authors.forename: A
authors.initials: A
authors.lastname: Vaccaro
authors.forename: C
authors.initials: C
authors.lastname: Fabiano
authors.forename: S
authors.initials: S
authors.lastname: Magrin
authors.forename: R
authors.initials: R
authors.lastname: Di Stefano
authors.forename: C
authors.initials: C
authors.lastname: Bonura
authors.forename: L
authors.initials: L
authors.lastname: Pagliaro
authors.forename: A
authors.initials: A
authors.lastname: Craxì
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha